| 23.33 0.14 (0.6%) | 10-28 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 29.65  |
1-year : | 32.59 |
| Resists | First : | 25.39 |
Second : | 27.9 |
| Pivot price | 22.95 |
|||
| Supports | First : | 21.31 | Second : | 17.73 |
| MAs | MA(5) : | 22.55  |
MA(20) : | 23.27 |
| MA(100) : | 27.55 |
MA(250) : | 22.35 |
|
| MACD | MACD : | -1.5 |
Signal : | -1.8 |
| %K %D | K(14,3) : | 39.5 |
D(3) : | 28.1 |
| RSI | RSI(14): 42.7 |
|||
| 52-week | High : | 37.47 | Low : | 10.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ANRO ] has closed below upper band by 39.7%. Bollinger Bands are 43.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 23.51 - 23.6 | 23.6 - 23.7 |
| Low: | 22.58 - 22.68 | 22.68 - 22.78 |
| Close: | 23.17 - 23.34 | 23.34 - 23.52 |
Alto Neuroscience, Inc. operates as a biopharmaceutical entity in the clinical stage, specializing in the creation of novel psychiatric medications. Its development pipeline includes ALTO-100, an investigational therapy targeting individuals affected by major depressive disorder (MDD) and post-traumatic stress disorder. Also in its portfolio is ALTO-300, a small molecule designed to function as both a melatonergic agonist and serotonergic antagonist, exhibiting antidepressant properties for MDD patients. For addressing the cognitive impairments linked with schizophrenia, Alto Neuroscience is advancing ALTO-101, an innovative small molecule phosphodiesterase 4 inhibitor. The company's therapeutic candidates further extend to ALTO-203, a pioneering small-molecule histamine H3 receptor inverse agonist intended for MDD patients experiencing heightened anhedonia, and ALTO-202, an orally available antagonist of the GluN2B subunit of the NMDA receptor, also under investigation for MDD. Beyond these individual drug candidates, the firm is engaged in developing novel drug combinations that demonstrate synergistic pharmacodynamic effects. Crucially, Alto Neuroscience leverages an advanced AI-enabled biomarker platform that synthesizes data concerning patients' brain activity and behavioral patterns. This platform's purpose is to accurately identify which individuals are most likely to respond positively to its cutting-edge product candidates. Alto Neuroscience, Inc., established in 2019, maintains its headquarters in Los Altos, California.
Sat, 24 Oct 2026
Alto Neuroscience, Inc. Estimates – NYSE:ANRO - TradingView
Thu, 15 Oct 2026
Alto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold (NYSE:ANRO) - Seeking Alpha
Wed, 14 Oct 2026
Here's Why You Should Add ANRO Stock to Your Portfolio Now - Yahoo Finance
Sat, 10 Oct 2026
Alto Neuroscience Inc. Research & Ratings | ANRO - Barron's
Thu, 01 Oct 2026
Form 4 Alto Neuroscience Inc For: 1 October By Investing.com - Investing.com Nigeria
Thu, 01 Oct 2026
Exercising options at $2.35, Alto Neuroscience (ANRO)'s CFO sells shares. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 39 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 87.1 (%) |
| Shares Short | 4,660 (K) |
| Shares Short P.Month | 3,840 (K) |
| EPS | -2.31 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.8 % |
| Return on Equity (ttm) | -49.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -68 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -10.1 |
| PEG Ratio | 0 |
| Price to Book value | 3.73 |
| Price to Sales | 0 |
| Price to Cash Flow | -13.41 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|